Clinical Trials
16 trialsNCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00565851 2025-12-30
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05446870 2025-10-01
MK-4830-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00227721 2020-12-02
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01196429 2019-08-08
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00569673 2018-07-18
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT00354601 2017-08-30
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02469116 2016-08-19
Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Washington University School of Medicine
Phase 2 Terminated
NCT00090610 2015-02-25
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Duke University
Phase 2 Completed
NCT00183794 2014-05-22
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
University of Southern California
Phase 2 Completed
NCT00504257 2014-02-06
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00069160 2012-10-12
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00296816 2012-08-23
TEACO
Sanofi
Phase 2 Completed